| 1 |
NCT03142217 |
Withdrawn |
Characterization of the Profile of Dysarthria in Huntington's Disease, Using the Clinical Evaluation Battery of Dysarthria |
- Dysarthria
- Huntington Disease
|
- Other: Study of dysarthria in patients with Huntington's disease
|
Interventional
|
Not Applicable |
- Centre Hospitalier Universitaire, Amiens
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Analysis of the Clinical Evaluation Battery of Dysarthria using criteria to establish a clinical profile specific to Huntington's disease
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT03142217 |
PI2015_843_0005 |
Huntington |
March 26, 2015 |
March 1, 2017 |
March 1, 2017 |
May 5, 2017 |
May 5, 2017 |
|
|
|
| 2 |
NCT01554033 |
Unknown † |
Study of Huntington Patients in Connection With European Huntington's Disease Network (EHDN) |
|
|
Observational
|
|
- Seoul National University Hospital
- European Huntington's Disease Network
|
Other |
- Observational Model: Case-Crossover
- Time Perspective: Cross-Sectional
|
|
200 |
All |
1 Year to 80 Years (Child, Adult, Older Adult) |
NCT01554033 |
H-0902-023-271 |
|
May 2009 |
May 2015 |
May 2015 |
March 14, 2012 |
March 19, 2012 |
|
- Department of Neurology, Seoul National University Hospital
Seoul, Korea, Republic of
|
|
| 3 |
NCT02876445 |
Completed |
Caregiver Burden in Huntington's Disease |
- Caregiver of Huntington's Disease Patient
|
- Other: ZARIT Burden Interview
|
Interventional
|
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Evaluation with ZARIT's scale of the burden level of the management of a patient with Huntington's disease by his caregiver
- Measuring social impact of the disease using the under score of ZARIT's scale for the patient and the caregiver
- Measuring professional impact of of the disease using the under score of ZARIT's scale for the patient and the caregiver
|
179 |
All |
18 Years and older (Adult, Older Adult) |
NCT02876445 |
NI10059 |
PHRI-HD |
March 2011 |
March 2016 |
March 2016 |
August 23, 2016 |
August 23, 2016 |
|
- Henri Mondor Hospital
Creteil, France
|
|
| 4 |
NCT02197130 |
Completed
Has Results |
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease |
|
- Drug: PF-02545920
- Other: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in the Total Motor Score (TMS) Assessment of the Unified Huntington Disease Rating Scale (UHDRS) After 26 Weeks of Treatment.
- Number of Participants That Met White Blood Count (WBC) and Absolute Neutrophil Count (ANC) Stopping Criteria
- Number of Participants With Adverse Events
- (and 12 more...)
|
272 |
All |
30 Years to 65 Years (Adult, Older Adult) |
NCT02197130 |
A8241021
2014-001291-56 |
|
September 2014 |
September 2016 |
October 2016 |
July 22, 2014 |
November 17, 2017 |
November 17, 2017 |
- The Kirklin Clinic of UAB Hospital
Birmingham, Alabama, United States - The University of Alabama at Birmingham
Birmingham, Alabama, United States - University of Alabama at Birmingham
Birmingham, Alabama, United States - (and 54 more...)
|
|
| 5 |
NCT03119246 |
Unknown † |
Beta Testing of a New Assessment in Huntington's Disease (HD) |
|
|
Interventional
|
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
- School of Biosciences - Cardiff University
- University Hospital of Wales
- (and 4 more...)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- All dysfunction or disorder of huntington patient measured by means of a new battery assessments
- Difference on motor score between patient and healthy volontary measured by motor tests of the revised Core Assessment Protocol
- Difference on cognitive score between patient and healthy volontary measured by cognitive tests of the revised Core Assessment Protocol
- (and 3 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03119246 |
P150201 |
CAPIT-HD Beta |
June 2016 |
March 2018 |
March 2018 |
April 18, 2017 |
April 18, 2017 |
|
- Henri Mondor Hospital
Creteil, France
|
|
| 6 |
NCT02006472 |
Completed |
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease |
|
- Drug: Pridopidine
- Other: Placebo
|
Interventional
|
Phase 2 |
- Teva Branded Pharmaceutical Products, R&D Inc.
- European Huntington's Disease Network
- Huntington Study Group
- Teva Pharmaceutical Industries
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at week 26
- Change from Baseline in modified Physical Performance Test (mPPT)
- Summary of participants with Adverse Events
|
408 |
All |
21 Years and older (Adult, Older Adult) |
NCT02006472 |
TV7820-CNS-20002
2013-001888-23 |
|
February 28, 2014 |
July 31, 2016 |
August 31, 2016 |
December 10, 2013 |
August 21, 2018 |
|
- Teva Investigational Site 12199
La Jolla, California, United States - Teva Investigational Site 12204
Los Angeles, California, United States - Teva Investigational Site 12201
Englewood, Colorado, United States - (and 55 more...)
|
|
| 7 |
NCT03628235 |
Not yet recruiting |
HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States |
|
- Behavioral: Online survey
|
Observational
|
|
- CHDI Foundation, Inc.
- IQVIA
|
Other / Industry |
- Observational Model: Other
- Time Perspective: Prospective
|
- Quantify the indirect costs associated with productivity loss for HDGECs and companions
- Quantify out-of-pocket expenses for HDGECs and companions
- Identify the indirect costs associated with informal care received for HDGECs
- (and 3 more...)
|
240 |
All |
21 Years and older (Adult, Older Adult) |
NCT03628235 |
C-001117-1 |
|
December 1, 2018 |
March 31, 2021 |
March 31, 2021 |
August 14, 2018 |
August 14, 2018 |
|
|
|
| 8 |
NCT03342053 |
Active, not recruiting |
Study in Huntington's Disease Patients Who Participated in Prior Investigational Studies of ISIS 443139 |
|
|
Interventional
|
Phase 2 |
- Ionis Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of treatment-emergent adverse events [safety and tolerability]
|
46 |
All |
25 Years and older (Adult, Older Adult) |
NCT03342053 |
ISIS 443139-CS2 |
|
November 27, 2017 |
December 2019 |
December 2019 |
November 14, 2017 |
November 16, 2018 |
|
- University of British Columbia
Vancouver, British Columbia, Canada - Charite University Berlin
Berlin, Germany - Ruhr-University of Bochum
Bochum, Germany - (and 6 more...)
|
|
| 9 |
NCT01306929 |
Completed |
Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease |
|
|
Interventional
|
Phase 2 |
- Teva Branded Pharmaceutical Products, R&D Inc.
- Teva Pharmaceutical Industries
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of subjects with at least one adverse event
- Unified Huntington's Disease Rating Scale (UHDRS) Total Motor Score
|
235 |
All |
Child, Adult, Older Adult |
NCT01306929 |
ACR16C015 |
OPEN-HART |
March 1, 2011 |
January 5, 2018 |
January 5, 2018 |
March 2, 2011 |
March 14, 2018 |
|
- Teva Investigational Site 045
Indianapolis, Indiana, United States - Teva Investigational Site 024
Iowa City, Iowa, United States - Teva Investigational Site 028
Baltimore, Maryland, United States - (and 9 more...)
|
|
| 10 |
NCT01485965 |
Completed |
A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease |
|
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the effect of food on the repeated dose pharmacokinetics of SEN0014196 at 100 mg once daily in subjects with Huntington's disease
- Pharmacodynamics
- To determine the safety and tolerability of repeated doses of SEN0014196 at 100 mg once daily in subjects with Huntington's disease
|
26 |
All |
25 Years to 65 Years (Adult, Older Adult) |
NCT01485965 |
S015-007 |
|
November 2011 |
November 2012 |
December 2012 |
December 6, 2011 |
March 20, 2013 |
|
- University of California San Diego
La Jolla, California, United States - University of California Davis Medical Center
Sacramento, California, United States - Washington University
St. Louis, Missouri, United States - (and 4 more...)
|
|
| 11 |
NCT01485952 |
Completed |
An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196 |
|
- Drug: SEN0014196 (Low Dose)
- Drug: SEN0014196 (High Dose)
- Drug: Placebo
|
Interventional
|
Phase 1 |
- Siena Biotech S.p.A.
- Seventh Framework Programme
- European Huntington's Disease Network
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To determine the change from baseline of a series of pharmacodynamic markers in peripheral blood mononuclear cells
- To determine the safety and tolerability following repeated doses of SEN0014196 over two weeks at two dose levels in patients with Huntington's disease
- To determine the pharmacokinetics of repeated doses of SEN0014196 at two dose levels when administered over two weeks in patients with Huntington's disease
|
55 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01485952 |
S015-004
CTA Number: 2010-021563-32 |
PADDINGTON |
March 2011 |
November 2011 |
November 2011 |
December 6, 2011 |
November 25, 2015 |
|
- Universitätsklinik Ulm, Neurologie
Ulm, Germany
|
|
| 12 |
NCT00497159 |
Completed |
A Study of the Novel Drug Dimebon in Patients With Huntington's Disease |
|
- Other: Placebo
- Drug: Dimebon
|
Interventional
|
Phase 2 |
- Medivation, Inc.
- Huntington Study Group
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To assess the safety and tolerability of Dimebon during 3 months of treatment in subjects with Huntington's Disease.
- To assess the impact of Dimebon during 3 months of treatment on cognitive, motor, and overall function in subjects with Huntington's Disease.
- To assess the pharmacokinetics of Dimebon.
|
91 |
All |
29 Years and older (Adult, Older Adult) |
NCT00497159 |
DIM05 |
DIMOND |
July 2007 |
June 2008 |
June 2008 |
July 6, 2007 |
June 8, 2015 |
|
- Huntington Study Group
Rochester, New York, United States
|
|
| 13 |
NCT02494778 |
Terminated |
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease |
|
|
Interventional
|
Phase 2 |
- Teva Branded Pharmaceutical Products, R&D Inc.
- Teva Pharmaceutical Industries
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of participants with adverse events
- Proportion of subjects (%) who prematurely discontinued from the study
- Proportion of subjects (%) who prematurely discontinued from the study due to AEs
|
248 |
All |
21 Years and older (Adult, Older Adult) |
NCT02494778 |
TV7820-CNS-20016
2015-000904-24 |
Open PRIDE-HD |
September 24, 2015 |
January 12, 2018 |
January 12, 2018 |
July 10, 2015 |
August 21, 2018 |
|
- Teva Investigational Site 12204
Los Angeles, California, United States - Teva Investigational Site 12201
Englewood, Colorado, United States - Teva Investigational Site 12196
Washington, District of Columbia, United States - (and 43 more...)
|
|
| 14 |
NCT03761849 |
Not yet recruiting
New |
A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease |
|
- Drug: RO7234292
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from Baseline in the Composite Unified Huntington's Disease Rating Scale (cUHDRS)
- Change From Baseline in the TFC Score
- Change From Baseline in Total Motor Score (TMS)
- (and 16 more...)
|
660 |
All |
25 Years to 65 Years (Adult, Older Adult) |
NCT03761849 |
BN40423 |
|
December 31, 2018 |
March 1, 2022 |
August 1, 2022 |
December 3, 2018 |
December 3, 2018 |
|
|
|
| 15 |
NCT03252535 |
Recruiting |
Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease |
|
- Biological: Cellavita HD lower dose
- Biological: Cellavita HD higher dose
- Other: Placebo
|
Interventional
|
Phase 2 |
- Azidus Brasil
- Cellavita Pesquisa Científica Ltda
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Effective Dose
- Improvement of UHDRS domains
- Clinical worsing over the treatment
- (and 4 more...)
|
35 |
All |
21 Years to 65 Years (Adult, Older Adult) |
NCT03252535 |
ADORE-DH
52375916.1.0000.5412 |
ADORE-DH |
April 18, 2018 |
April 15, 2020 |
September 30, 2020 |
August 17, 2017 |
September 18, 2018 |
|
- Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda.
Valinhos, São Paulo, Brazil
|
|
| 16 |
NCT02263430 |
Unknown † |
PINS Stimulator System for Deep Brain Stimulation in Huntington's Disease |
|
- Device: Deep Brain Stimulation
|
Interventional
|
Not Applicable |
- Beijing Pins Medical Co., Ltd
- Beijing Tiantan Hospital
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Unified Huntington's Disease Rating Scale(UHDRS)
|
8 |
All |
18 Years and older (Adult, Older Adult) |
NCT02263430 |
PINS-007 |
|
December 2016 |
December 2018 |
December 2018 |
October 13, 2014 |
October 14, 2016 |
|
|
|
| 17 |
NCT01412125 |
Recruiting |
Study of Biomarkers That Predict the Evolution of Huntington's Disease |
|
- Other: Huntington patient evaluation
- Other: Healthy subject evaluation
|
Observational
|
|
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Unified Huntington Disease Rating Scale (UHDRS)
- Mattis Dementia Rating Scale
- Trail Making test A et B
- (and 8 more...)
|
1800 |
All |
18 Years and older (Adult, Older Adult) |
NCT01412125 |
P090302 |
BIOHD |
September 2003 |
January 2021 |
January 2021 |
August 9, 2011 |
October 9, 2014 |
|
- Hôpital Henri Mondor
Creteil, France
|
|
| 18 |
NCT01879267 |
Completed |
Exercise Effects in Huntington's Disease |
|
- Behavioral: Exercise training
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Unified Huntington's Disease Rating Scale (UHDRS)
|
40 |
Male |
30 Years to 60 Years (Adult) |
NCT01879267 |
KEK-ZH-Nr. 2009-0119 |
|
January 2012 |
January 2018 |
January 2018 |
June 17, 2013 |
June 13, 2018 |
|
- University Hospital Zurich, Division of Neurology
Zurich, ZH, Switzerland
|
|
| 19 |
NCT02563418 |
Unknown † |
Feasibility of a Video-oculography in Patients With Huntington's Disease VOG-HD Study |
|
|
Interventional
|
Not Applicable |
- University Hospital, Angers
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- saccadic measures with the eye tracker
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT02563418 |
AOI 2013 - 11 |
VOG-HD |
May 2014 |
May 2017 |
|
September 30, 2015 |
September 30, 2015 |
|
- Centre Hospitalier Universitaire
Angers, France
|
|
| 20 |
NCT02639871 |
Recruiting |
Dynamic Neuroimaging Biomarkers in Huntington's Disease |
- Brain Neuroimaging Biomarkers in Huntington Disease
|
|
Observational
|
|
- Assistance Publique - Hôpitaux de Paris
- CEA
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Cerebral synthesis rate of creatine phosphate
- Cerebral brain glutamate concentrations
- Cerebral pH values.
- (and 11 more...)
|
80 |
All |
18 Years and older (Adult, Older Adult) |
NCT02639871 |
P140708
2015-A00793-46 |
HDeNERGY |
June 28, 2016 |
June 2018 |
September 2018 |
December 28, 2015 |
November 30, 2017 |
|
- APHP - Pitié Salpetriere Hospital
Paris, France
|
|
| 21 |
NCT03664804 |
Recruiting |
Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease |
|
- Other: No Study Drug was Administered in this Study
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Change from Baseline in the Following Clinical Endpoints at 3, 9, and 15 Months: cUHDRS, TFC, TMS, SDMT, SWR Test, and IS
- Change from Baseline in Biomarkers of Neuronal Injury (e.g., CSF NfL and tau) at 3, 9, and 15 Months
- Change from Baseline in Brain Atrophy Endpoints (e.g., Whole Brain Volume Decline, Caudate Volume Decline) as Determined by Brain MRI, at 3, 9, and 15 Months
- (and 4 more...)
|
100 |
All |
25 Years to 65 Years (Adult, Older Adult) |
NCT03664804 |
BN40422 |
|
December 8, 2018 |
March 31, 2021 |
March 31, 2021 |
September 11, 2018 |
December 4, 2018 |
|
- University of California Davis Medical System
Sacramento, California, United States - Rocky Mountain Movement Disorders Center
Englewood, Colorado, United States - Georgetown University; Research Division, Psychiatry
Washington, District of Columbia, United States - (and 13 more...)
|
|
| 22 |
NCT03599076 |
Not yet recruiting |
Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease |
|
|
Observational
|
|
- BioSensics
- University of Rochester
|
Industry / Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
|
50 |
All |
Child, Adult, Older Adult |
NCT03599076 |
1R44NS103648-01 |
|
July 2018 |
December 2019 |
December 2019 |
July 25, 2018 |
July 25, 2018 |
|
|
|
| 23 |
NCT02728115 |
Active, not recruiting |
Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease |
|
- Biological: Cellavita HD Lower Dose
- Biological: Cellavita HD Higher dose
|
Interventional
|
Phase 1 |
- Azidus Brasil
- Cellavita Pesquisa Científica Ltda
- Azidus Brasil Scientific Research and Development Ltda
|
Industry / Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Safety of Cellavita HD by periodic monitoring changes at adverse events, vital signs, laboratory tests, ECG and incidence of benign and malignant neoplasms
- Preliminary efficacy of Cellavita HD by global clinical response (CIBIS) and UHDRS improvement
- Preliminary efficacy of Cellavita HD by comparison of the inflammatory markers
- (and 3 more...)
|
6 |
Male |
21 Years to 65 Years (Adult, Older Adult) |
NCT02728115 |
SAVE-DH
51005115.9.0000.5412 |
SAVE-DH |
January 15, 2018 |
January 2023 |
August 2023 |
April 5, 2016 |
September 18, 2018 |
|
- Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda.
Valinhos, São Paulo, Brazil
|
|
| 24 |
NCT02926820 |
Completed |
Working Memory Training in Huntington's Disease |
|
|
Interventional
|
Not Applicable |
- York University
- North York General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adherence to training (defined by completing the intervention within the recommended time frame)
- Digit Span subtest from the Wechsler Memory Scales - third edition
- Spatial Span subtest from the Wechsler Memory Scales - third edition
- (and 6 more...)
|
9 |
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT02926820 |
NYGH 15-0001 |
|
February 2015 |
March 2016 |
March 2016 |
October 6, 2016 |
October 10, 2016 |
|
- North York General Hospital
Toronto, Ontario, Canada
|
|
| 25 |
NCT02519036 |
Completed |
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-HTTRx in Patients With Early Manifest Huntington's Disease |
|
- Drug: IONIS HTTRx
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- Ionis Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Safety (The number of participants with adverse events)
- Tolerability (The number of participants with adverse events)
- CSF Pharmacokinetics (The observed CSF drug concentration)
|
46 |
All |
25 Years to 65 Years (Adult, Older Adult) |
NCT02519036 |
ISIS 443139-CS1 |
|
August 6, 2015 |
November 1, 2017 |
November 1, 2017 |
August 10, 2015 |
October 5, 2018 |
|
- University of British Columbia
Vancouver, British Columbia, Canada - Charite University Berlin
Berlin, Germany - Ruhr-University of Bochum
Bochum, Germany - (and 6 more...)
|
|
| 26 |
NCT01019473 |
Terminated |
Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea |
- Huntington's Disease
- Chorea
|
- Drug: AFQ056
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Efficacy of AFQ056 on the severity of chorea in Huntington's disease measured by Unified Huntington's Disease Rating Scale (UHDRS) Maximal Chorea score.
- Potential effect of AFQ056 on the motor, cognitive, behavioral and functional assessments using UHDRS.
- Potential effect of AFQ056 on functional and quality of life scales, neuropsychiatric assessments and cognitive assessments in Huntington's Disease patients
|
44 |
All |
30 Years to 85 Years (Adult, Older Adult) |
NCT01019473 |
CAFQ056A2207
2009-011743-39 |
|
November 2009 |
August 2011 |
|
November 25, 2009 |
September 23, 2011 |
|
- Novartis Investigator Site
Berlin, Germany - Novartis Investigator Site
Bochum, Germany - Novartis Investigator Site
Munster, Germany - (and 7 more...)
|
|
| 27 |
NCT02342548 |
Terminated
Has Results |
Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021 |
|
- Drug: 20 mg BID of PF-02545920
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events
- Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
- Number of Participants With Vital Signs Data Meeting Categorical Summarization Criteria
- (and 8 more...)
|
188 |
All |
30 Years to 66 Years (Adult, Older Adult) |
NCT02342548 |
A8241022
2014-004900-31
OPEN LABEL TO A8241021 |
|
February 25, 2015 |
February 6, 2017 |
February 6, 2017 |
January 21, 2015 |
April 23, 2018 |
April 23, 2018 |
- The Kirkland Clinic of UAB Hospital
Birmingham, Alabama, United States - University of Alabama at Birmingham
Birmingham, Alabama, United States - Mayo Clinic Arizona
Scottsdale, Arizona, United States - (and 47 more...)
|
|
| 28 |
NCT03434548 |
Not yet recruiting |
Huntington's Disease 123 |
|
|
Observational
|
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Other
|
- Change in binding profile of four discrete molecular PET markers
|
150 |
All |
21 Years to 75 Years (Adult, Older Adult) |
NCT03434548 |
HD123 |
|
April 1, 2019 |
March 31, 2024 |
March 31, 2024 |
February 15, 2018 |
September 18, 2018 |
|
|
|
| 29 |
NCT03575676 |
Recruiting |
Efficacy and Safety of SOM3355 in Huntington's Disease Chorea |
|
- Drug: SOM3355 100mg BID
- Drug: SOM3355 200mg BID
- Drug: Placebo BID
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- UHDRS (Unified Huntington's Disease Rating Scale) Total Maximal Chorea (TMC) score
- Clinical Global Impression of Change (CGIC) scale
- Patient Global Impression of Change (PGIC) scale
- (and 6 more...)
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT03575676 |
SOMCT02
2018-000203-16 |
|
August 8, 2018 |
April 2019 |
June 2019 |
July 2, 2018 |
September 20, 2018 |
|
- Hospital Clínic de Barcelona
Barcelona, Spain - Hospital de la Santa Creu i Sant Pau
Barcelona, Spain - Hospital Universitari Vall d'Hebron
Barcelona, Spain - Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Spain
|
|
| 30 |
NCT02509793 |
Recruiting |
A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine) |
|
|
Interventional
|
Phase 4 |
- William Ondo, MD
- H. Lundbeck A/S
- The Methodist Hospital System
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Score on the Questionnaire for Impulsive Disorders in Parkinson's Disease
- Change in Score on the Geriatric Depression Scale
- Change in Score on the Barrat Impulsivity Scale
- (and 4 more...)
|
20 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02509793 |
Pro00013929
HSC-MS-13-0878 |
|
April 2014 |
July 2019 |
July 2019 |
July 28, 2015 |
November 9, 2018 |
|
- Methodist Neurological Institute
Houston, Texas, United States
|
|
| 31 |
NCT01502046 |
Completed |
Neuroprotection by Cannabinoids in Huntington's Disease |
|
- Drug: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
- GW Pharmaceuticals Ltd.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Serious Adverse Events reported
- Changes in the UHDRs Score
- Changes in the BDNF levels (Brain-derived Neurotrophic Factor), oxidative stress (due to mitochondrial dysfunction) and proinflammatory cytokines in plasma
- Changes in the BDNF levels (Brain-derived Neurotrophic Factor), oxidative stress (due to mitochondrial dysfunction) and proinflammatory cytokines in cerebrospinal fluid.
|
25 |
All |
18 Years and older (Adult, Older Adult) |
NCT01502046 |
SAT-HD
2010-024227-24 |
|
September 2011 |
June 2012 |
June 2012 |
December 30, 2011 |
February 1, 2013 |
|
- Hospital Universitario Ramón y Cajal
Madrid, Spain
|
|
| 32 |
NCT01411150 |
Completed |
Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study |
|
- Drug: Creatine Monohydrate
|
Interventional
|
Phase 2 |
- Massachusetts General Hospital
- National Institutes of Health (NIH)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety
- Tolerability
- Clinical measures
- Biological Markers of Disease Progression
|
38 |
All |
26 Years and older (Adult, Older Adult) |
NCT01411150 |
2009P000642 |
Pre-CREST-X |
May 2009 |
September 2012 |
September 2012 |
August 8, 2011 |
February 10, 2014 |
|
- Massachusetts General Hospital
Charlestown, Massachusetts, United States
|
|
| 33 |
NCT01411163 |
Completed |
Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability |
|
- Drug: Creatine monohydrate
|
Interventional
|
Phase 2 |
- Massachusetts General Hospital
- National Institutes of Health (NIH)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety
- Tolerability
- Clinical measures
- Biological Markers of Disease Progression
|
24 |
All |
26 Years and older (Adult, Older Adult) |
NCT01411163 |
2010P000511 |
Pre-CREST-2X |
April 2010 |
May 2013 |
May 2013 |
August 8, 2011 |
February 10, 2014 |
|
- Massachusetts General Hospital
Charlestown, Massachusetts, United States
|
|
| 34 |
NCT01412151 |
Completed
Has Results |
Creatine Safety & Tolerability in Huntington's Disease |
- Huntington's Disease (HD)
|
- Drug: Creatine monohydrate
|
Interventional
|
Phase 2 |
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tolerability
- Clinical Measures Resources Not Available to Complete Secondary Analyses.
- Biological Markers of Disease Progression
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT01412151 |
2005P000530 |
CREST-X |
April 2005 |
November 2011 |
November 2011 |
August 9, 2011 |
March 9, 2018 |
December 28, 2012 |
- Massachusetts General Hospital
Charlestown, Massachusetts, United States
|
|
| 35 |
NCT01590589 |
Completed |
REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN) |
- Huntington Disease
- Huntington's Disease
|
|
Observational
|
|
- European Huntington's Disease Network
- European Huntington's Disease Network
|
Other |
- Observational Model: Cohort
- Time Perspective: Other
|
- Phenotypical characteristics of HD
|
10000 |
All |
Child, Adult, Older Adult |
NCT01590589 |
REGISTRY 3.0 |
REGISTRY |
June 2004 |
June 30, 2017 |
June 30, 2017 |
May 3, 2012 |
September 15, 2017 |
|
- Universitätsklinik für Psychiatrie, Neuropsychiatrische Ambulanz
Graz, Austria - Universitätsklinik Innsbruck, Neurologie
Innsbruck, Austria - UCL-St Luc, Centre de génétique humaine
Brussels, Belgium - (and 137 more...)
|
|
| 36 |
NCT03296176 |
Recruiting |
Metabolomic Study in Huntington's Disease (METABO-HD) |
|
|
Interventional
|
Not Applicable |
- University Hospital, Angers
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
|
150 |
All |
20 Years to 70 Years (Adult, Older Adult) |
NCT03296176 |
49RC17_0086 |
|
October 9, 2017 |
September 2019 |
September 2019 |
September 28, 2017 |
November 1, 2017 |
|
|
|
| 37 |
NCT03515213 |
Recruiting |
Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease |
|
- Drug: Fenofibrate
- Drug: Placebo
|
Interventional
|
Phase 2 |
- University of California, Irvine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in PGC-1alpha from Baseline to Month 6
- Change in Fenofibrate level from Baseline to Month 6
- Change in Motor Scores from Baseline to Month 6
- (and 3 more...)
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03515213 |
2016-3022 |
|
April 27, 2017 |
December 31, 2019 |
December 31, 2019 |
May 3, 2018 |
May 8, 2018 |
|
- University of California, Irvine
Irvine, California, United States
|
|
| 38 |
NCT00277355 |
Completed
Has Results |
Pilot Study of Minocycline in Huntington's Disease |
|
- Drug: minocycline
- Drug: Matching placebo
|
Interventional
|
Phase 2
Phase 3 |
- Merit Cudkowicz
- FDA Office of Orphan Products Development
- Huntington Study Group
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [LOCF Imputation Method]
- Change From Baseline to Month 18 in the Total Functional Capacity (TFC) Scale [Regression Based Multiple Imputation Method]
|
114 |
All |
18 Years and older (Adult, Older Adult) |
NCT00277355 |
FD-R-002588
DOMINO |
|
April 2006 |
October 2008 |
November 2008 |
January 16, 2006 |
April 19, 2013 |
April 19, 2013 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Colorado Neurological Institute
Englewood, Colorado, United States - University of Florida
Gainesville, Florida, United States - (and 9 more...)
|
|
| 39 |
NCT01860339 |
Enrolling by invitation |
Growth and Development of the Striatum in Huntington's Disease |
|
|
Observational
|
|
- Peggy C Nopoulos
- CHDI Foundation, Inc.
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of Iowa
|
Other / NIH |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- Volume of brain structures as measured by Magnetic Resonance Imaging (MRI)
- Quantitative assessment of cognitive skills and motor skills
|
700 |
All |
6 Years to 25 Years (Child, Adult) |
NCT01860339 |
200507759
4R01NS055903-08 |
Kids-HD |
July 2005 |
June 30, 2019 |
June 30, 2019 |
May 22, 2013 |
June 20, 2018 |
|
- University of Iowa Hospitals and Clinics, Department of Psychiatry
Iowa City, Iowa, United States
|
|
| 40 |
NCT01735981 |
Completed |
The Effect of Video Game Exercise on Dynamic Balance and Gait in Individuals With Huntington's Disease |
|
- Other: Video game exercise using Dance Dance Revolution
- Other: hand-held video game
|
Interventional
|
Not Applicable |
- Anne Kloos
- Ohio State University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- gait parameters
- Tinetti Mobility Test
- Four Square Step Test
- (and 4 more...)
|
24 |
All |
18 Years to 79 Years (Adult, Older Adult) |
NCT01735981 |
2008H0109 |
|
June 2008 |
November 2010 |
June 2012 |
November 28, 2012 |
November 28, 2012 |
|
- The Ohio State University Atwell Hall
Columbus, Ohio, United States
|
|
| 41 |
NCT00724048 |
Completed |
A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease |
|
- Drug: ACR16 10 mg
- Drug: ACR16 22.5 mg
- Drug: ACR16 45 mg
- Other: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Teva Pharmaceutical Industries
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Sum score of items 4-10 and 13-15 of the UHDRS motor assessment
- Clinical Global Impressions (CGI)
- Adverse event profile
|
227 |
All |
30 Years and older (Adult, Older Adult) |
NCT00724048 |
ACR16 C009 |
HART |
October 2008 |
June 2011 |
June 2011 |
July 29, 2008 |
July 22, 2016 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - University of California
San Diego, California, United States - Colorado Neurological Institute
Littleton, Colorado, United States - (and 25 more...)
|
|
| 42 |
NCT00665223 |
Completed |
A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's Disease |
|
|
Interventional
|
Phase 3 |
- Teva Pharmaceutical Industries
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The primary objective is to assess the effects of ACR16 on voluntary motor function in HD patients, as defined as the sum score of items 4-10 and 13-15 of the UHDRS motor assessment (a modified motor score mMS) at 26 weeks of treatment.
- Safety and tolerability assessed from adverse event profile.
- The effects of ACR16 on CGI, cognitive function, behaviour and symptoms of depression and anxiety.
|
437 |
All |
30 Years and older (Adult, Older Adult) |
NCT00665223 |
ACR16 C008 |
MermaiHD |
April 2008 |
June 2011 |
June 2011 |
April 23, 2008 |
July 21, 2016 |
|
- LKH -Univ. Klinikum Graz, Universitaetsklinik fur Psychiatrie Graz
Graz, Styria, Austria - Innsbruck Medical University, Anichstraße 35
Innsbruck, Tyrol, Austria - University Hospital Gasthuisberg
Leuven, Flemish Brabant, Belgium - (and 28 more...)
|
|
| 43 |
NCT01884181 |
Completed |
Accelerated Diffusion MRI for Diagnosis of Hungtington Disease |
|
|
Observational
|
|
- Wang . Jiun-Jie
- National Health Research Institutes, Taiwan
- Chang Gung Memorial Hospital
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Feasibility study on healthy human.
- Diagnosis Huntington Disease
|
80 |
All |
20 Years to 70 Years (Adult, Older Adult) |
NCT01884181 |
102-1056B |
|
January 2014 |
December 2017 |
December 2017 |
June 21, 2013 |
July 18, 2018 |
|
- ChangGung Memorial Hospital, Linkou
Taoyuan, Taiwan
|
|
| 44 |
NCT02855476 |
Recruiting |
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease |
|
|
Observational
|
|
- University College, London
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of CSF samples banked
- Huntingtin protein level in cerebrospinal fluid
- Kynurenine metabolites in cerebrospinal fluid
|
600 |
All |
21 Years to 75 Years (Adult, Older Adult) |
NCT02855476 |
15/0519 |
HDClarity |
January 2017 |
July 2019 |
July 2020 |
August 4, 2016 |
September 5, 2018 |
|
- John Hopkins University
Baltimore, Maryland, United States - Wake Forest University
Winston-Salem, North Carolina, United States - University of Texas Health Science Center
Houston, Texas, United States - (and 11 more...)
|
|
| 45 |
NCT01937923 |
Completed |
A Pre-Cellular Therapy Observational Study in Early Huntington's Disease |
|
|
Observational
|
|
- University of California, Davis
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Rate of change from baseline in white matter volume on magnetic resonance imaging (MRI) brain scan.
- Rate of change from baseline on the UHDRS total motor score
- Rate of change from baseline on the Total Functional Capacity score
|
29 |
All |
18 Years and older (Adult, Older Adult) |
NCT01937923 |
455690
DR2A-05415 |
PRE-CELL |
August 2013 |
July 2016 |
July 2016 |
September 10, 2013 |
November 1, 2016 |
|
- UC Davis Medical Center, Clinical Research Center
Sacramento, California, United States
|
|
| 46 |
NCT02990676 |
Recruiting |
Exploring Computerised Cognitive Training for People With Huntington's Disease |
|
- Behavioral: Computerised cognitive training
|
Interventional
|
Not Applicable |
- Cardiff University
- Jacque and Gloria Gossweiler Foundation
- Health and Care Research Wales
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Number of participants able to complete the feasibility study as measured by retention rate
- Number of participants able to complete computerised HAPPYneuron pro cognitive training as assessed by task performance and the quality of the data generated.
- Symbol digit modality test
- (and 14 more...)
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT02990676 |
1535-16
HF-16-1152
210821 |
CogTrainHD |
January 25, 2017 |
September 2019 |
September 2019 |
December 13, 2016 |
January 30, 2018 |
|
- Cardiff University
Cardiff, United Kingdom
|
|
| 47 |
NCT01458470 |
Completed |
A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease |
|
- Drug: Memantine
- Other: Placebo
|
Interventional
|
Phase 2 |
- University of British Columbia
- Huntington Society of Canada
- Huntington Study Group
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Utility of TRACK-HD study endpoints in a clinical trial setting
- Neuropsychiatric and Cognitive Test Scores
|
19 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01458470 |
H11-01364 |
MITIGATE-HD |
September 2011 |
August 2012 |
November 2012 |
October 24, 2011 |
March 18, 2014 |
|
- The Centre for Huntington Disease
Vancouver, British Columbia, Canada
|
|
| 48 |
NCT03225846 |
Recruiting |
Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease |
|
- Drug: WVE-120102
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Safety: Number of patients with adverse events (AEs)
- Safety: Severity of AEs
- Safety: Number of patients with serious AEs (SAEs)
- (and 7 more...)
|
48 |
All |
25 Years to 65 Years (Adult, Older Adult) |
NCT03225846 |
WVE-HDSNP2-001 |
PRECISION-HD2 |
July 17, 2017 |
September 2019 |
September 2019 |
July 21, 2017 |
November 2, 2018 |
|
- Centre For Movement Disorders
Toronto, Ontario, Canada - Centre Hospitalier de l-Universite de Montreal
Montreal, Quebec, Canada - Szpital Sw. Wojciecha
Gdańsk, Poland - (and 2 more...)
|
|
| 49 |
NCT03225833 |
Recruiting |
Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease |
|
- Drug: WVE-120101
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Safety: Number of patients with adverse events (AEs)
- Safety: Severity of AEs
- Safety: Number of patients with serious AEs (SAEs)
- (and 7 more...)
|
48 |
All |
25 Years to 65 Years (Adult, Older Adult) |
NCT03225833 |
WVE-HDSNP1-001 |
PRECISION-HD1 |
July 17, 2017 |
September 2019 |
September 2019 |
July 21, 2017 |
November 2, 2018 |
|
- Centre For Movement Disorders
Toronto, Ontario, Canada - Center Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada - Szpital Sw. Wojciecha
Gdańsk, Poland - (and 2 more...)
|
|
| 50 |
NCT00387270 |
Completed |
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease |
|
|
Interventional
|
Phase 1
Phase 2 |
- Medivation, Inc.
- Huntington Study Group
|
Industry / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose-limiting toxicities
- Unified Huntington's Disease Rating Scale
|
9 |
All |
18 Years and older (Adult, Older Adult) |
NCT00387270 |
DIM03
DIMOND |
|
October 2006 |
March 2007 |
March 2007 |
October 12, 2006 |
January 4, 2008 |
|
- Huntington Study Group
Rochester, New York, United States
|
|
| 51 |
NCT02550275 |
Unknown † |
Social Cognition in Huntington's Disease: Cognitive Study and Functional and Morphological Imaging |
|
- Behavioral: neuropsychological test
- Radiation: MRI
|
Interventional
|
Not Applicable |
- University Hospital, Angers
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- the achievement of social cognition process in Huntington's disease using the total score of the scale 15-TOM
|
80 |
All |
20 Years to 70 Years (Adult, Older Adult) |
NCT02550275 |
AOI 201409 |
COSIMH |
January 2015 |
February 2018 |
|
September 15, 2015 |
September 15, 2015 |
|
|
|
| 52 |
NCT02218567 |
Unknown † |
Behavioural Problems in Huntington Disease : Analysis and Enhancement of Caregiver and Patient Experience |
|
- Behavioral: questionnaire qualilty of life
- Behavioral: psychological interview
- Behavioral: psychological tests
- (and 3 more...)
|
Interventional
|
Not Applicable |
- University Hospital, Angers
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- The Huntington's Disease health-related Quality of Life questionnaire
|
80 |
All |
18 Years and older (Adult, Older Adult) |
NCT02218567 |
2014-A00327-40 |
HUNTEXPERT |
June 2014 |
March 2016 |
|
August 18, 2014 |
August 18, 2014 |
|
- University Hospital of Angers
Angers, Maine et Loire, France
|
|
| 53 |
NCT02481674 |
Recruiting |
VX15/2503 Treatment for Huntington's Disease |
|
- Drug: VX15/2503
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Vaccinex Inc.
- Huntington Study Group
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety and tolerability as measured by drug related adverse event frequency and laboratory test abnormalities
- Immunogenicity of VX15/2503 as measured by the frequency and titer of anti-drug antibodies
- Brain volumes measured by MRI
- (and 15 more...)
|
276 |
All |
21 Years and older (Adult, Older Adult) |
NCT02481674 |
VX15/2503-N-131 |
SIGNAL |
July 2015 |
May 2020 |
May 2020 |
June 25, 2015 |
October 19, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - University of California, San Diego
La Jolla, California, United States - University of California San Francisco
San Francisco, California, United States - (and 29 more...)
|
|
| 54 |
NCT01696708 |
Completed |
Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease |
|
- Other: 31-Phosphorus RMN Spectroscopy
|
Interventional
|
Not Applicable |
- Institut National de la Santé Et de la Recherche Médicale, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Ratio of Inorganic Phosphate (Pi) over phosphocreatine (PCr): Pi/PCr
- Correlation between primary outcome measure and clinical parameters
- Study of longitudinal changes in Pi/PCr ratio over time.
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT01696708 |
C12-49
2012-A01063-40 |
PRO-MH2 |
December 6, 2012 |
November 2015 |
November 2015 |
October 1, 2012 |
March 9, 2017 |
|
- Brain and Spine Institute (ICM)
Paris, France
|
|
| 55 |
NCT00980694 |
Completed |
Bioavailability of Ubiquinol in Huntington Disease |
|
- Dietary Supplement: ubiquinol
|
Interventional
|
Phase 1 |
- University of Rochester
- Kaneka Corporation
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- serum coenzyme Q10 levels
|
6 |
All |
18 Years and older (Adult, Older Adult) |
NCT00980694 |
UQ01 |
|
September 2009 |
July 2012 |
July 2012 |
September 21, 2009 |
May 27, 2016 |
|
- University of Rochester
Rochester, New York, United States
|
|
| 56 |
NCT00075140 |
Completed |
Family Health After Predictive Huntington Disease (HD) Testing |
|
- Genetic: Mutation in the gene
|
Observational
|
|
- National Institute of Nursing Research (NINR)
|
NIH |
|
- Impact of a positive HD test or presence of HD on a family members perceptions of: health problems, emotional and functional health status, resources/strategies for managing problems, helpfulness, and services needed to help family members cope.
- Describe the health care needs, management strategies, and needs for health and social services of a broader sample of relatives/significant others in families in which a person has a gene mutation for HD.
|
422 |
All |
Child, Adult, Older Adult |
NCT00075140 |
1R01NR007970-01 |
|
September 2001 |
October 2008 |
October 2008 |
January 5, 2004 |
January 16, 2009 |
|
- The University of Iowa College of Nursing
Iowa City, Iowa, United States
|
|
| 57 |
NCT02956148 |
Completed |
Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers |
|
- Radiation: Radioligand [18F]MNI-659
|
Interventional
|
Early Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- The longitudinal changes of PDE10A enzyme availability in the caudate, putamen, and globus pallidus of Huntington's Disease Gene Expansion Carriers by comparison of the follow-up and initial PET measurements.
|
45 |
All |
18 Years to 73 Years (Adult, Older Adult) |
NCT02956148 |
CHDIKI1401 |
LONGPDE10 |
September 6, 2015 |
March 10, 2017 |
March 10, 2017 |
November 7, 2016 |
September 6, 2018 |
|
- The Memory Clinic, Rigshopitalet
Copenhagen, Denmark - Leiden University Medical Center, Department of Neurology
Leiden, Netherlands - University of Oslo, Nevrologisk poliklinikk
Oslo, Norway - (and 4 more...)
|
|
| 58 |
NCT02336633 |
Recruiting |
Resveratrol and Huntington Disease |
|
- Dietary Supplement: Resveratrol
- Other: Placebo
|
Interventional
|
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- rate of caudate atrophy
- UHDRS (Unified Huntington Disease Rating Scale)
- TFC (Total Functional Capacity)
- ratio of inorganic phosphate/phosphocreatine
|
102 |
All |
18 Years and older (Adult, Older Adult) |
NCT02336633 |
P130918 |
REVHD |
July 2015 |
January 2019 |
January 2019 |
January 13, 2015 |
April 17, 2018 |
|
- Institut du Cerveau et de la Moelle, Hôpital de la Pitié Salpêtrière
Paris, France
|
|
| 59 |
NCT01806896 |
Completed
Has Results |
Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease |
|
- Drug: PF-02545920
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
- Number of Participants With Laboratory Abnormalities Meeting the Criteria for Potential Clinical Concern (Without Regard to Baseline Abnormality)
- Number of Participants With Potentially Clinically Significant Vital Signs Findings
- (and 9 more...)
|
37 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01806896 |
A8241016
2012-004432-31 |
|
September 2013 |
January 2015 |
January 2015 |
March 7, 2013 |
December 14, 2017 |
December 14, 2017 |
- Centre d'Investigation Clinique (CIC)/ Institut du Cerveau et de la Möelle Epinière (ICM)
Paris Cedex 13, France
|
|
| 60 |
NCT03344601 |
Recruiting |
PHysical Activity and Exercise Outcomes in Huntington's Disease |
|
- Behavioral: physical activity
|
Interventional
|
Not Applicable |
- Cardiff University
- CHDI Foundation, Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Data completeness
- Recruitment
- Retention
- (and 16 more...)
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT03344601 |
SPON 1631-17 |
PACE-HD |
February 16, 2018 |
October 16, 2019 |
December 31, 2019 |
November 17, 2017 |
June 25, 2018 |
|
- Re+Active Therapy and Wellness Centre/ UCLA
Los Angeles, California, United States - Teacher's College, Columbia University
New York, New York, United States - George Huntington Institute
Münster, Germany - (and 3 more...)
|
|
| 61 |
NCT00608881 |
Terminated
Has Results |
Coenzyme Q10 in Huntington's Disease (HD) |
|
- Drug: coenzyme Q10
- Other: placebo
|
Interventional
|
Phase 3 |
- Massachusetts General Hospital
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of Rochester
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived))
- Change in Total Functional Capacity (TFC) Score From Baseline to Month 60
- Change in Functional Checklist Score From Baseline to Month 60
- (and 12 more...)
|
609 |
All |
16 Years and older (Child, Adult, Older Adult) |
NCT00608881 |
2CARE 01.00
5U01NS052592
5R01NS052619 |
2CARE |
March 2008 |
November 2014 |
May 2015 |
February 6, 2008 |
March 30, 2016 |
March 30, 2016 |
- University of Alabama At Birmingham, Pediatric Neurology Childrens, Harbor Bldg Suite 314, 1600 7Th Avenue South
Birmingham, Alabama, United States - Mayo Clinic Arizona, 13400 East Shea Boulevard, Csu-Cp21B
Scottsdale, Arizona, United States - WASHINGTON REGIONAL MEDICAL CENTER, 3215 N. North Hills Blvd
Fayetteville, Arkansas, United States - (and 46 more...)
|
|
| 62 |
NCT03764215 |
Recruiting
New |
Nilotinib in Huntington's Disease |
|
|
Interventional
|
Phase 1 |
|
Other |
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants experiencing any Adverse events and Serious Adverse Events
- CSF levels of biomarkers linked to Disease symptoms Chorea and behavioral symptoms
- Number of participants tolerating the drug by the ability of remaining on treatment
|
10 |
All |
25 Years to 90 Years (Adult, Older Adult) |
NCT03764215 |
2017-0440 |
Tasigna HD |
November 15, 2018 |
November 30, 2019 |
May 31, 2020 |
December 5, 2018 |
December 5, 2018 |
|
- Georgetown University Medical Center
Washington, District of Columbia, United States
|
|
| 63 |
NCT02464293 |
Active, not recruiting |
A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington's Disease |
|
- Other: Mindfulness-based cognitive therapy
|
Interventional
|
Not Applicable |
- Lancaster University
- Manchester University NHS Foundation Trust
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- depression post intervention
- depression at 3 months
- depression at 1 year
- (and 29 more...)
|
16 |
All |
18 Years and older (Adult, Older Adult) |
NCT02464293 |
EHDN Seed Fund Project 561
15/NW/0238 |
|
June 2015 |
December 2017 |
May 2018 |
June 8, 2015 |
June 2, 2017 |
|
- Central Manchester University Hospitals NHS Foundation Trust
Manchester, United Kingdom
|
|
| 64 |
NCT01451463 |
Completed
Has Results |
Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease |
|
|
Observational
|
|
- Ohio State University
- Lundbeck LLC
|
Other / Industry |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Tinetti Mobility Test Score
- Five Times Sit to Stand Test
|
11 |
All |
18 Years and older (Adult, Older Adult) |
NCT01451463 |
2010H0312 |
|
April 2010 |
April 2013 |
April 2013 |
October 13, 2011 |
November 24, 2017 |
October 19, 2017 |
- The Ohio State University Medical Center
Columbus, Ohio, United States
|
|
| 65 |
NCT01574053 |
Recruiting |
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort |
|
|
Observational
|
|
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
|
15000 |
All |
18 Years and older (Adult, Older Adult) |
NCT01574053 |
Enroll -HD |
|
July 2012 |
January 2062 |
January 2062 |
April 10, 2012 |
November 6, 2018 |
|
- University of Alabama
Birmingham, Alabama, United States - St. Joseph's Hospital and Medical Center
Phoenix, Arizona, United States - University of California - Irvine Medical Center
Irvine, California, United States - (and 159 more...)
|
|
| 66 |
NCT02551705 |
Unknown † |
Functional Imaging of Social Cognition in Premanifest Huntington's Disease |
|
- Other: functional Imaging
|
Interventional
|
Not Applicable |
- Universitaire Ziekenhuizen Leuven
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Investigator)
- Primary Purpose: Basic Science
|
- Significant group differences in brain activation for perceiving emotional vs neutral faces by following random effects analyses
|
40 |
All |
18 Years to 90 Years (Adult, Older Adult) |
NCT02551705 |
S58457 |
FISCIP |
October 2015 |
October 2017 |
October 2017 |
September 16, 2015 |
September 16, 2015 |
|
|
|
| 67 |
NCT00146211 |
Completed |
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease |
|
- Drug: Ethyl-EPA (Miraxion™)
|
Interventional
|
Phase 3 |
- Amarin Neuroscience Ltd
- Huntington Study Group
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- To compare with placebo the effect of ethyl-EPA on the Total Motor Score-4 component (TMS) of the Unified Huntington's Disease Rating Scale (UHDRS) over a 6-month period of observation.
- To compare with placebo the effect of ethyl-EPA over a 6-month period of observation on, 1) Chorea (UHDRS Total Motor Score Scale); 2) Total Motor Score component (TMS) of the UHDRS; and, 3) Clinical Global Impression (CGI) score.
|
300 |
All |
35 Years and older (Adult, Older Adult) |
NCT00146211 |
AN01.01.0011 |
|
September 2005 |
August 2007 |
July 2007 |
September 7, 2005 |
December 27, 2007 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Mayo Clinic Arizona
Scottsdale, Arizona, United States - University of California San Diego
La Jolla, California, United States - (and 38 more...)
|
|
| 68 |
NCT01834911 |
Completed |
Effect of Tetrabenazine on Stroop Interference in HD |
|
- Drug: Tetrabenazine withdrawal
|
Interventional
|
Phase 4 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Stroop Interference Score
|
2 |
All |
18 Years and older (Adult, Older Adult) |
NCT01834911 |
L-10,830 |
|
March 2013 |
January 1, 2018 |
January 1, 2018 |
April 18, 2013 |
April 2, 2018 |
|
- Terence Cardinal Cooke Health Care Center
New York, New York, United States
|
|
| 69 |
NCT00902889 |
Completed |
Deep Brain Stimulation of the Globus Pallidus in Huntington's Disease |
|
|
Interventional
|
Phase 1 |
- Heinrich-Heine University, Duesseldorf
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy of stimulation of GPI versus GPR (UHDRS Scale)
- Effect of treatment on cognitive functions (neuropsychological tests)
- Effects of treatment on electrophysiological tests
- (and 3 more...)
|
6 |
All |
18 Years and older (Adult, Older Adult) |
NCT00902889 |
Huntington |
|
May 2009 |
April 2012 |
July 2012 |
May 15, 2009 |
September 11, 2012 |
|
- Functional Neurosurgery and Stereotaxy, Department of Neurosurgery University Hospital Duesseldorf
Duesseldorf, NW, Germany
|
|
| 70 |
NCT03417583 |
Not yet recruiting |
Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients |
|
- Other: Protocol Intervention Group
|
Interventional
|
Not Applicable |
- Vanderbilt University Medical Center
- Teva Pharmaceuticals USA
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Other
|
- Change in quality of life- Concern with Death and Dying
- Change in quality of life- Meaning and Purpose
- Change in quality of life- Ability to Participate in Social Roles and Activities
- (and 5 more...)
|
100 |
All |
21 Years and older (Adult, Older Adult) |
NCT03417583 |
172030 |
|
October 2018 |
October 2021 |
October 2021 |
January 31, 2018 |
September 11, 2018 |
|
- Vanderbilt Medical Center
Nashville, Tennessee, United States
|
|
| 71 |
NCT00514774 |
Unknown † |
Ursodiol in Huntington's Disease |
|
- Drug: ursodiol
- Drug: placebo
|
Interventional
|
Phase 1 |
- Oregon Health and Science University
- Huntington Study Group
- Huntington Society of Canada
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Safety measures (complete blood count, chemistry profile, electrocardiogram, urinalysis)
- Tolerability measures (adverse event severity)
- Pharmacokinetic measures (Serum and CSF levels of bile acids)
|
21 |
All |
18 Years and older (Adult, Older Adult) |
NCT00514774 |
00001927 |
UDCA-HD |
August 2007 |
June 2009 |
June 2009 |
August 10, 2007 |
February 5, 2009 |
|
- Oregon Health & Science University
Portland, Oregon, United States
|
|
| 72 |
NCT02074410 |
Terminated |
Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease |
|
- Drug: OMS643762
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Assess the Safety of OMS643762
- Motor function
- Cognition
- (and 2 more...)
|
22 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02074410 |
OMS824-HTD-002 |
|
January 2014 |
October 15, 2014 |
October 15, 2014 |
February 28, 2014 |
October 22, 2018 |
|
- San Diego, California, United States
- Englewood, Colorado, United States
- Gainesville, Florida, United States
- (and 6 more...)
|
|
| 73 |
NCT02231580 |
Terminated
Has Results |
Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients |
|
- Drug: BN82451B
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Numbers of Patients Experiencing Treatment Emergent Adverse Events (TEAEs).
- Area Under the Plasma Concentration Time Curve (AUC)
- Peak Plasma Concentration (Cmax)
- (and 23 more...)
|
17 |
Male |
20 Years to 70 Years (Adult, Older Adult) |
NCT02231580 |
8-55-52966-005
2013-002899-41 |
|
September 1, 2014 |
March 31, 2016 |
March 31, 2016 |
September 4, 2014 |
January 29, 2018 |
January 29, 2018 |
|
|
| 74 |
NCT01357681 |
Completed |
Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study) |
|
- Drug: (2)-epigallocatechin-3-gallate (EGCG)
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Charite University, Berlin, Germany
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change of cognitive functions (UHDRS-Cognition: composite score of Stroop test, Verbal fluency & Symbol Digit Modalities Test) after 12 months in comparison to baseline
- UHDRS Motor Score
- UHDRS Behavioural Score
- (and 13 more...)
|
54 |
All |
18 Years and older (Adult, Older Adult) |
NCT01357681 |
2010-023941-31 |
ETON |
September 2011 |
May 2015 |
May 2015 |
May 23, 2011 |
June 16, 2015 |
|
- Department of Neuropsychiatry
Berlin, Germany - Neurologische Klinik der Ruhr-Universität Bochum
Bochum, Germany - Universitätsklinikum Ulm, Klinik für Neurologie
Ulm, Germany
|
|
| 75 |
NCT02535884 |
Recruiting |
Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD) |
|
- Device: ACTIVA® PC neurostimulator (Model 37601)
|
Interventional
|
Not Applicable |
- Heinrich-Heine University, Duesseldorf
- KKS Netzwerk
- Medtronic
- (and 3 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- UHDRS-TMS difference
- UHDRS-Chorea difference
- UHDRS-bradykinesia difference
- (and 10 more...)
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT02535884 |
KKS-198
DRKS00006785 |
HD-DBS |
July 2014 |
June 30, 2020 |
October 31, 2020 |
August 31, 2015 |
July 30, 2018 |
|
- Medizinische Universität Innsbruck
Innsbruck, Austria - CHU Amiens Hôpital nord, Department of neurosurgery and Department of neurology
Amiens, France - Hôpital Roger Salengro, Service de Neurologie et Pathologie du mouvement
Lille Cedex, France - (and 9 more...)
|
|
| 76 |
NCT03193099 |
Recruiting |
Decoding Presymptomatic White Matter Changes in Huntington Disease |
- Huntington Disease
- White Matter Alterations
|
- Other: Brain imaging
- Other: Neurological assessments
- Behavioral: Psychological assessments
- Behavioral: Behavioural assessments
|
Interventional
|
Not Applicable |
- Institut National de la Santé Et de la Recherche Médicale, France
- University College, London
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Detection by Diffusion-weighted spectroscopy of abnormal white matter changes prior to the onset of Huntington disease comparing HTT mutation carriers and non HTT mutation carriers over one year
- Detection by Diffusion-weighted spectroscopy of abnormal white matter changes over one year as an intersubject evolution
- Detection by Diffusion Tensor Imaging of abnormal white matter changes prior to the onset of Huntington disease comparing HTT mutation carriers and non HTT mutation carriers over one year.
- (and 4 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03193099 |
C16-115
2017-A00589-44 |
Win-HD |
July 11, 2017 |
December 30, 2018 |
December 30, 2018 |
June 20, 2017 |
August 29, 2017 |
|
- Brain and Spine Institute
Paris, France
|
|
| 77 |
NCT01590602 |
Completed |
REGISTRY-JHD - an Observational Study of the European Huntington's Disease Network (EHDN) |
- Huntington Disease, Juvenile
|
|
Observational
|
|
- European Huntington's Disease Network
- European Huntington's Disease Network
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Evalutation of assessments for HD
|
78 |
All |
Child, Adult, Older Adult |
NCT01590602 |
REGISTRY-JHD |
JHD |
November 2011 |
June 30, 2017 |
June 30, 2017 |
May 3, 2012 |
September 15, 2017 |
|
- University Hospital of Ulm, Dept. of Neurology
Ulm, Germany - Sheffield Children's Hospital, Department of Clinical Genetics
Sheffield, United Kingdom
|
|
| 78 |
NCT00178360 |
Completed |
Effects of Music Therapy on Huntington's Disease |
|
- Behavioral: Music Therapy
|
Interventional
|
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
|
- To examine the feasibility and tolerability of a treatment program of MT for subjects with HD.
- To determine if MT improves the mood and motor features of HD while improving quality of life.
|
11 |
All |
18 Years and older (Adult, Older Adult) |
NCT00178360 |
10336 |
|
July 2004 |
December 2008 |
June 2010 |
September 15, 2005 |
August 22, 2011 |
|
- University of Rochester Medical Center
Rochester, New York, United States
|
|
| 79 |
NCT00051324 |
Active, not recruiting |
Neurobiological Predictors of Huntington's Disease (PREDICT-HD) |
|
|
Observational
|
|
- University of Iowa
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Refine the prediction of disease diagnosis (motor conversion)
- Characterize disease progression prior to diagnosis.
- Establish possible validity and reliability of disease measures.
|
1500 |
All |
18 Years and older (Adult, Older Adult) |
NCT00051324 |
199904075
R01NS040068 |
PREDICT-HD |
August 2002 |
August 31, 2017 |
December 2018 |
January 9, 2003 |
November 29, 2017 |
|
|
|
| 80 |
NCT01590888 |
Completed
Has Results |
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease |
|
|
Interventional
|
Phase 2 |
- Prana Biotechnology Limited
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety and Tolerability of PBT2 in Patients With HD
- Change From Baseline in Cognitive Test Battery - Composite z Scores
- Change From Baseline in Motor Function
- (and 8 more...)
|
109 |
All |
25 Years and older (Adult, Older Adult) |
NCT01590888 |
PBT2-203 |
Reach2HD |
April 2012 |
July 2013 |
February 2014 |
May 3, 2012 |
July 18, 2016 |
July 18, 2016 |
- University of California San Diego
San Diego, California, United States - Colorado Neurological Institute
Englewood, Colorado, United States - University of Connecticut Health Center
Farmington, Connecticut, United States - (and 16 more...)
|
|
| 81 |
NCT00670709 |
Completed
Has Results |
Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease |
|
|
Observational
|
|
- University of California, Los Angeles
- High Q Foundation
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Quantitative Electroencephalography Absolute Delta Power.
- Quantitative Electroencephalography Absolute Alpha Power.
|
42 |
All |
21 Years and older (Adult, Older Adult) |
NCT00670709 |
QEEG and HD |
HD |
September 2006 |
February 2008 |
February 2008 |
May 2, 2008 |
February 11, 2013 |
August 16, 2010 |
- UCLA Laboratory of Brain, Behavior,a nd PHarmacology
Los Angeles, California, United States
|
|
| 82 |
NCT02061722 |
Completed |
[PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET. |
|
- Radiation: PET Imaging with [18F]MNI-659
|
Interventional
|
Early Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- The primary outcome measure will be the distribution volume (VT) in the striatum (caudate and putamen), globus pallidus, and ventral striatum estimated using kinetic and graphical analysis. Thalamus, cortex and cerebellum will also be examined.
|
90 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02061722 |
CHDIKI1201/PET-HD-PDE10A |
PEARL-HD |
January 2013 |
May 2016 |
May 2016 |
February 13, 2014 |
June 1, 2016 |
|
- The Memory Clinic, Rigshopitalet
Copenhagen, Denmark - Leiden University Medical Center, Department of Neurology
Leiden, Netherlands - University of Oslo, Nevrologisk poliklinikk
Oslo, Norway - (and 5 more...)
|
|
| 83 |
NCT00712426 |
Terminated |
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) |
|
- Drug: Creatine Monohydrate
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Massachusetts General Hospital
- University of Rochester
- National Center for Complementary and Integrative Health (NCCIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Total Functional Capacity
- Clinical symptoms (changes in other UHDRS scores); safety (frequency of adverse events); tolerability (proportion of subjects completing study at assigned dosage level), quality of life, other biological markers.
|
553 |
All |
18 Years and older (Adult, Older Adult) |
NCT00712426 |
2007P000827
U01AT000613 |
CREST-E |
September 2009 |
December 2014 |
January 2015 |
July 10, 2008 |
March 11, 2016 |
|
- University of Alabama
Birmingham, Alabama, United States - University of California, Irvine
Irvine, California, United States - University of California Davis
Sacramento, California, United States - (and 44 more...)
|
|
| 84 |
NCT00026988 |
Completed |
Creatine Therapy for Huntington's Disease |
|
|
Interventional
|
Phase 1
Phase 2 |
- National Center for Complementary and Integrative Health (NCCIH)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
|
64 |
All |
18 Years and older (Adult, Older Adult) |
NCT00026988 |
R01AT000613-01 |
|
October 2001 |
|
June 2006 |
November 16, 2001 |
August 18, 2006 |
|
- Steven Hersch, M.D., Ph.D.
Boston, Massachusetts, United States - Andrew Feigin, M.D.
Long Island, New York, United States - Karen Marder, M.D.
New York, New York, United States - Peter Como, Ph.D.
Rochester, New York, United States
|
|
| 85 |
NCT00212316 |
Completed |
Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD) |
|
- Drug: sodium phenylbutyrate
|
Interventional
|
Phase 2 |
- University of Rochester
- HP Therapeutics Foundation
- Massachusetts General Hospital
- (and 6 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Proportion of subjects able to complete treatment (Week 16)
- Secondary safety and tolerability outcomes at Weeks 1, 4, 5, 10, 16, & 20 include:
- adverse events,
- (and 13 more...)
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT00212316 |
R01NS45242 |
|
August 2005 |
|
June 2006 |
September 21, 2005 |
August 15, 2012 |
|
- University of Alabama
Birmingham, Alabama, United States - University of California—San Diego
San Diego, California, United States - University of Iowa Hospital and Clinics
Iowa City, Iowa, United States - (and 5 more...)
|
|
| 86 |
NCT02215616 |
Completed |
A Clinical Study in Subjects With Huntington's Disease to Assess Efficacy and Safety of Three Oral Doses of Laquinimod |
|
- Drug: Laquinimod
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Teva Branded Pharmaceutical Products, R&D Inc.
- Teva Pharmaceutical Industries
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline in UHDRS TMS (1.0 mg qd)
- Percent atrophy from baseline in caudate volume in patients treated with laquinimod (1.0 mg qd)
|
352 |
All |
21 Years to 55 Years (Adult) |
NCT02215616 |
TV5600-CNS-20007
2014-000418-75 |
LEGATO-HD |
November 24, 2014 |
June 19, 2018 |
June 19, 2018 |
August 13, 2014 |
October 9, 2018 |
|
- Teva Investigational Site 12566
La Jolla, California, United States - Teva Investigational Site 12565
Los Angeles, California, United States - Teva Investigational Site 12567
San Francisco, California, United States - (and 50 more...)
|
|
| 87 |
NCT01085266 |
Terminated |
An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease |
|
- Drug: Dimebon (latrepirdine)
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
362 |
All |
30 Years and older (Adult, Older Adult) |
NCT01085266 |
DIM20EXT |
HORIZON PLUS |
February 2010 |
June 2011 |
|
March 11, 2010 |
October 12, 2016 |
|
|
|
| 88 |
NCT00539747 |
Completed |
Making Sense of a Positive Genetic Test Result for Huntington Disease |
|
|
Observational
|
|
- National Human Genome Research Institute (NHGRI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Retrospective
|
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT00539747 |
999908005
08-HG-N005 |
|
October 1, 2007 |
|
August 5, 2008 |
October 5, 2007 |
July 2, 2017 |
|
- Johns Hopkins University
Baltimore, Maryland, United States - National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
Bethesda, Maryland, United States - University of Pittsburgh
Pittsburgh, Pennsylvania, United States - Baylor College of Medicine
Houston, Texas, United States
|
|
| 89 |
NCT00920946 |
Completed |
A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease |
|
- Drug: Dimebon
- Other: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- A comparison between the mean changes from baseline in the Dimebon 20 mg TID treatment group and the placebo group on the MMSE
- A comparison of the distributions of the CIBIC-plus (ADCS CGIC)in the Dimebon 20 mg TID treatment group and the placebo group
- A comparison between the mean changes from baseline of the Dimebon 20 mg TID treatment group and the placebo group on the NPI
- (and 2 more...)
|
403 |
All |
30 Years and older (Adult, Older Adult) |
NCT00920946 |
DIM20 |
HORIZON |
July 2009 |
July 2011 |
|
June 15, 2009 |
October 12, 2016 |
|
- Scottsdale, Arizona, United States
- Davis, California, United States
- Irvine, California, United States
- (and 34 more...)
|
|
| 90 |
NCT00632645 |
Completed |
Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride |
|
- Drug: Olanzapine
- Drug: Xenazine
- Drug: Tiapridal
|
Interventional
|
Phase 3 |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- the Independence scale
- motor scale
- Psychiatric scale
- (and 5 more...)
|
180 |
All |
18 Years and older (Adult, Older Adult) |
NCT00632645 |
P060211 |
NEUROHD |
April 2009 |
April 28, 2017 |
April 28, 2017 |
March 11, 2008 |
January 19, 2018 |
|
- CHU Henri Mondor
Creteil, France
|
|
| 91 |
NCT00652457 |
Unknown † |
Study of Memantine to Treat Huntington's Disease |
|
|
Interventional
|
Phase 4 |
- University of California, San Diego
- Forest Laboratories
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- sensitive neuropsychological battery
- behavioral and functional measures at three and six months of treatment
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT00652457 |
MEM-HD |
|
|
|
|
April 3, 2008 |
April 3, 2008 |
|
- University of California, San Diego
La Jolla, California, United States - University of Kansas Medical Center
Kansas City, Kansas, United States - Johns Hopkins Hospital
Baltimore, Maryland, United States
|
|
| 92 |
NCT00920699 |
Completed
Has Results |
Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL) |
|
|
Interventional
|
Phase 2 |
- Johns Hopkins University
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Tolerability as Assessed by Ability to Complete the Study on the Originally Randomized Treatment Assignment.
- 8OHdG Levels
- CoQ10 Levels
|
90 |
All |
18 Years and older (Adult, Older Adult) |
NCT00920699 |
PREQUEL-01.00
NIH grant: 1 R01 NS060118-01A1 |
PREQUEL |
February 2010 |
March 2012 |
March 2012 |
June 15, 2009 |
September 25, 2017 |
September 25, 2017 |
- University of California Davis
Sacramento, California, United States - Colorado Neurological Institute
Englewood, Colorado, United States - University of Miami School of Medicine
Miami, Florida, United States - (and 10 more...)
|
|
| 93 |
NCT02101957 |
Unknown † |
Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103) |
|
|
Interventional
|
Phase 2
Phase 3 |
- University Hospital, Angers
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Unified Huntington's Disease Rating Scale motor
|
96 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02101957 |
PHRC2004-03bis |
|
October 2010 |
July 2015 |
|
April 2, 2014 |
April 2, 2014 |
|
|
|
| 94 |
NCT03034122 |
Recruiting |
Is Caffeine an Environmental Modifier in Huntington's Disease? |
|
|
Observational
|
|
- University Hospital, Lille
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in striatal volume
- Unified Huntington's Disease Rating Scale (UHDRS)
- SDMT -symbol digit modality test
- (and 4 more...)
|
100 |
All |
21 Years and older (Adult, Older Adult) |
NCT03034122 |
2015_67
2016-A00892-49 |
CrEAM-HD |
October 11, 2017 |
October 2021 |
October 2021 |
January 27, 2017 |
December 22, 2017 |
|
- Hôpital Roger Salengro, CHRU
Lille, France
|
|
| 95 |
NCT00095355 |
Completed |
Effects of Lithium and Divalproex`on Brain-Derived Neurotrophic Factor in Huntington's Disease |
|
- Drug: Lithium
- Drug: Divalproex
|
Interventional
|
Phase 2 |
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
35 |
All |
Child, Adult, Older Adult |
NCT00095355 |
050020
05-N-0020 |
|
October 2004 |
|
March 2005 |
November 3, 2004 |
March 4, 2008 |
|
- National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, Maryland, United States
|
|
| 96 |
NCT02507284 |
Active, not recruiting |
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease |
- Irritable Mood
- Huntington's Disease
|
- Drug: SRX246
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- Azevan Pharmaceuticals
- National Institute of Neurological Disorders and Stroke (NINDS)
- NeuroNEXT Network
|
Industry / NIH / Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Tolerability: Assess the proportion of completers
- Safety: Assess the proportion of participants who experience an adverse event
|
106 |
All |
18 Years and older (Adult, Older Adult) |
NCT02507284 |
AVN011
1U44NS090616-01A1 |
|
June 2016 |
October 2018 |
October 2018 |
July 23, 2015 |
August 17, 2018 |
|
- University of Alabama
Birmingham, Alabama, United States - UCLA, Neurology Clinic
Los Angeles, California, United States - UC Davis Medical Center, Department of Neurology, CTSC Clinical Research Center
Sacramento, California, United States - (and 19 more...)
|
|
| 97 |
NCT02134561 |
Unknown † |
Assessment of the Psychological, Cognitive and Social Resources of Applicants for Huntington's Disease and Presymptomatic Genetic Testing |
- Presymptomatic Huntington Disease
|
- Behavioral: psychological interview
- Radiation: MRI
- Other: cognitive tests
- Other: neurological tests
|
Interventional
|
Not Applicable |
- University Hospital, Angers
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Change from baseline total score of the psychological Unified Huntington's Disease Rating Scale at 2 years
|
25 |
All |
18 Years and older (Adult, Older Adult) |
NCT02134561 |
2013-A00088-37 |
PREHUNT |
September 2013 |
September 2017 |
|
May 9, 2014 |
May 9, 2014 |
|
- University Hospital of Angers
Angers, Pays de la Loire, France
|
|
| 98 |
NCT00277602 |
Completed |
Riluzole in Huntington's Disease |
|
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
|
537 |
All |
25 Years to 65 Years (Adult, Older Adult) |
NCT00277602 |
RIL_DE1_201 |
|
November 1999 |
July 2004 |
July 2004 |
January 16, 2006 |
February 17, 2012 |
|
|
|
| 99 |
NCT00029874 |
Completed |
Minocycline in Patients With Huntington's Disease |
|
|
Interventional
|
Phase 1
Phase 2 |
- FDA Office of Orphan Products Development
|
U.S. Fed |
- Allocation: Randomized
- Masking: Double
- Primary Purpose: Treatment
|
|
63 |
All |
18 Years and older (Adult, Older Adult) |
NCT00029874 |
FD-R-1968-01 |
|
September 2001 |
|
August 2003 |
January 25, 2002 |
March 25, 2015 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
|
| 100 |
NCT02453061 |
Recruiting |
A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease |
|
- Drug: Triheptanoin oil
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Institut National de la Santé Et de la Recherche Médicale, France
- Ultragenyx Pharmaceutical Inc
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- 31-Phosphorus Magnetic Resonance Spectroscopy
- volumetric magnetic resonance imaging
- motor function after 6 months
- (and 23 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT02453061 |
C14-62 |
TRIHEP3 |
June 2015 |
June 2017 |
June 2019 |
May 25, 2015 |
March 9, 2017 |
|
- Département de Génétique
Paris, France - Department of Neurology
Leiden The Netherlands, Netherlands
|
|
Create an RSS feed from your search for:
Download the search results for: